# Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a)

> **NCT04606602** · PHASE1 · COMPLETED · sponsor: **Silence Therapeutics plc** · enrollment: 70 (actual)

## Conditions studied

- Hyperlipidemias
- Dyslipidemias
- Elevated Lp(a)

## Interventions

- **DRUG:** SLN360
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04606602
- **Lead sponsor:** Silence Therapeutics plc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-18
- **Primary completion:** 2023-08-23
- **Final completion:** 2023-08-23
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2024-08-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04606602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04606602, "Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04606602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*